In an age of precision medicine, rapidly advancing biomarkers, and innovative cancer screening technologies, the demand for up-to-date information and tools is increasing like never before. The ACCC has been on the forefront of this demand for years, highlighting the expanding role of biomarkers in cancer diagnosis, prognosis, and treatment selection, as well as providing insights and tools to support multidisciplinary cancer care team members.
Through various educational initiatives, the ACCC deconstructs these complex advancements to deliver the clear and targeted information that multidisciplinary cancer care team members need to know. With access to these curated resources, team members can be confident in their ability to discuss the role of diagnostics and biomarker testing with their patients and caregivers, particularly those from underserved populations.
Key learning objectives for this area of focus include:
Discover how more than 400 patients with cancer have received life-changing, targeted treatment recommendations from the multidisciplinary team at Saint Luke’s Center for Precision Oncology—where care is tailored to the tumor, not just the diagnosis.1 To showcase their innovative work, ACCC presents a 5-part video series featuring insights from program champions and powerful stories from patient advocates.
Source: 1. https://www.saintlukeskc.org/center-precision-oncology
As the precision medicine testing landscape becomes increasingly complex, ACCC has curated actionable tip sheets to help cancer care teams navigate biomarker testing for gynecologic tumors, newly identified mutations, hereditary cancer syndromes as well as optimize the use of liquid biopsy and communicate biomarker test results effectively. Download these helpful guides today.
Consistent, affordable, and equitable access to biomarker testing remains elusive. Uneven coverage of guideline-concordant testing compounds anxiety and distress for patients insured by Medicaid. View a breakdown of states with pending or enacted legislation to expand biomarker testing access and find information on resources to aid its implementation, including a lexicon of relevant terminology for multidisciplinary care teams and a resource library with materials to support patients and providers alike.
Discover how TriHealth Cancer Institute has integrated biomarker testing and reporting of 12 genomic labs into their electronic health record (EHR) system and the positive impact of discrete genomic biomarker results on patient care and downstream revenue tracking.
Hear patient advocacy professionals discuss the impact of using patient-centered vocabulary during precision medicine conversations.
Discover how a statewide health system implemented a precision oncology navigator model and a decentralized clinical trial network to expand access across care settings. Viewers will gain practical insights to support participation, streamline workflows, and strengthen access to precision medicine.
Explore how screening location shapes access to hereditary cancer risk assessment—and what it takes to build equitable, sustainable screening-to-counseling pathways. This on-demand webinar offers practical strategies to expand community-based screening and strengthen follow-up care.
Discover how genetic counseling strengthens precision oncology by improving genomic test interpretation, treatment planning, and hereditary cancer risk assessment. This webinar highlights real-world implementation models and the clinical and operational value of fully integrated genetic counseling services.
Watch an expert panel discuss the role of pathologists as part of the multidisciplinary care team and learn how collaboration through each stage of the cancer care continuum can help guide treatments and optimize care coordination in this recording from a LinkedIn Live broadcast.
View the recording from a livestreamed webinar about the challenges of clinical variant interpretation. Learn how the adoption of clinical support decision tools is streamlining precision oncology workflows as well as elucidating complex variants and the hierarchy of data organization.
In recognition of Bladder Health Awareness Month, ACCC shares the results of a recent quality improvement study, which provides impactful steps cancer centers can take to mitigate disparities in bladder cancer.
Genetic testing and molecular profiling can be the key to better outcomes for patients with pancreatic cancer by allowing oncologists to implement more targeted therapies.
Hear about the evolution of artificial intelligence in precision oncology and the clinical impact of tech-based solutions.
Gain insights on reshaping multidisciplinary cancer care team workflows to enable laboratory professionals to improve biomarker testing efficiency.
Navigating the complex insurance process can be an overwhelming experience for patients who need biomarker testing. Financial navigators can play a crucial role in providing the best guidance and care by understanding the biomarker testing landscape and communicating complex details clearly.
This 20-minute, self-paced eCourse offers financial navigators foundational knowledge of biomarkers testing, and insurance guidelines. Learners will gain access to financial and educational resources, practice clear communication strategies to improve patient comprehension and explore best practices for prior authorization.
The first facility on Long Island, NY to offer next-generation sequencing with point-of-care genomic testing opened this May, and brought access to state of the art medical technology to patients in 6 different counties in the region.
Explore insights from this LinkedIn Live event highlighting the crucial role of pathologists within the multidisciplinary cancer care team.
Through a series of education projects, ACCC is committed to providing the resources the multidisciplinary cancer care team will need to navigate the complex precision medicine landscape and deliver next generation cancer care.
In the era of personalized medicine, biomarker testing is a tool the oncology workforce can and should leverage to deliver next generation cancer care.
